Approaches to de-escalation of antiplatelet treatment in stabilized post-myocardial infarction patients with high ischemic risk

References

• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177.
   PubMed Web of Science ®Google Scholar
• Collet J-P, Thiele H, Barbato E, et al., 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationThe Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2021. 42(14): 1289–1367.
   PubMed Web of Science ®Google Scholar
• Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145(3):e18–e114 .
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Galli M, Collet JP, et al. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention. 2022;17(17):e1371–e1396.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Mccabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057.
   PubMed Web of Science ®Google Scholar
• Becker RC, Bassand JP, Budaj A, et al., Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011. 32(23): 2933–2944.
   PubMed Web of Science ®Google Scholar
• Antman EM, Wiviott SD, Murphy SA, et al., Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis In myocardial infarction) analysis. J Am Coll Cardiol. 2008. 51(12): 2028–2033.
   PubMedGoogle Scholar
• Kupka D, Sibbing D. De-escalation of P2Y12 P2Y 12 receptor inhibitor therapy after acute coronary Syndromes in patients undergoing percutaneous coronary intervention. Korean Circ J. 2018;48(10):863–872.
   PubMed Web of Science ®Google Scholar
• Kim MH, Choi SY, Serebruany V. De-escalation of dual antiplatelet regimens in East Asian patients undergoing coronary intervention. Am J Ther. 2020;27(6):e611–e612.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Alexopoulos D, et al., Updated expert consensus statement on platelet function and genetic testing for guiding P2Y 12 P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019. 12(16): 1521–1537.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Rollini F, Storey RF, et al. International Expert Consensus on Switching Platelet P2Y12 receptor-inhibiting P2Y 12 Receptor–Inhibiting Therapies. Circulation. 2017;136(20):1955–1975.
   PubMed Web of Science ®Google Scholar
• Galli M, Angiolillo DJ. De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when? Front Cardiovasc Med. 2022;9:2307.
   Google Scholar
• Van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, et al. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J. 2021;42(10):1038–1046.
   PubMed Web of Science ®Google Scholar
• Carrabba N, Parodi G, Marcucci R, et al. Bleeding events and maintenance dose of prasugrel: BLESS pilot study. Open Heart. 2016;3(2):e000460.
   PubMedGoogle Scholar
• Li XY, Su GH, Wang GX, et al. Switching from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction undergoing successful percutaneous coronary intervention in real-world China: occurrences, reasons, and long-term clinical outcomes. Clin Cardiol. 2018;41(11):1446–1454.
   PubMed Web of Science ®Google Scholar
• de JC, Kim MH, Song K, et al. Pharmacodynamics and outcomes of a de-escalation strategy with half-dose prasugrel or ticagrelor in east asians patients with acute coronary syndrome: results from hope-tailor trial. J Clin Med. 2021;10(12):2699.
   PubMed Web of Science ®Google Scholar
• Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38(41):3070–3078.
   PubMed Web of Science ®Google Scholar
• Deharo P, Quilici J, Camoin-Jau L, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome according to on-treatment platelet reactivity: the TOPIC-VASP pre-specified analysis of the TOPIC randomized study. JACC Cardiovasc Interv. 2017;10(24):2560–2570.
   PubMed Web of Science ®Google Scholar
• Kim CJ, Park M-W, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398(10308):1305–1316.
   PubMed Web of Science ®Google Scholar
• Park MW, Kim CJ, Kim MC, et al. A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALOS-AMI trial. EuroIntervention. 2021;16(14):1170–1176.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kang J, Hwang D, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020;396(10257):1079–1089.
   PubMed Web of Science ®Google Scholar
• Hwang D, Lim Y-H, Park KW, et al., Prasugrel dose de-escalation therapy after complex percutaneous coronary intervention in patients with acute coronary syndrome: a post hoc analysis from the HOST-REDUCE-POLYTECH-ACS trial. JAMA Cardiol. 2022. 7(4): 418–426.
   PubMed Web of Science ®Google Scholar
• Y-J K, Lee BK, Park KW, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with STEMI. Korean Circ J. 2022;52(4):304–319.
   PubMed Web of Science ®Google Scholar
• Lee HS, Park KW, Kang J, et al. De-escalation of prasugrel results in higher percentage of patients within optimal range of platelet reactivity: analysis from the HOST-REDUCE-POLYTECH-ACS trial. Thromb Haemost. 2021;122(1):160–162.
   PubMedGoogle Scholar
• Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908–2913.
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754–762.
   PubMed Web of Science ®Google Scholar
• Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011;306(11):1215–1223.
   PubMed Web of Science ®Google Scholar
• Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: P2Y 12 -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36(27):1762–1771.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Cho JR, et al. Platelet function testing in contemporary clinical and interventional practice. Curr Treat Options Cardio Med. 2014;16(5):1–22.
   Google Scholar
• Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309–317.
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–857.
   PubMed Web of Science ®Google Scholar
• Harmsze AM, van Werkum JW, ten Berg JM, et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case–control case-control study. Eur Heart J. 2010;31(24):3046–3053.
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced-Function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–1830.
   PubMed Web of Science ®Google Scholar
• Galli M, Franchi F, Rollini F, et al. Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Rev Clin Pharmacol. 2021;14(8):963–978.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Rivas J, et al. Prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes: results of a randomized pharmacodynamic study in a feasibility investigation of rapid genetic testing. JACC Basic Transl Sci. 2020;5(5):419–428.
   PubMedGoogle Scholar
• Capodanno D, Angiolillo DJ, Lennon RJ, et al. ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: insights from the TAILOR-PCI Trial. J Am Heart Assoc. 2022;11(4):e024156.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovasc Interv. 2020;13(5):606–617.
   PubMed Web of Science ®Google Scholar
• Jeong YH, Oh JH, Yoon HJ, et al. Pharmacodynamic profile and prevalence of bleeding episode in east asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial. Thromb Haemost. 2021;121(10):1376–1386.
   PubMed Web of Science ®Google Scholar
• Hazarbasanov D, Velchev V, Finkov B, et al. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis. 2012;34(1):85–90.
   PubMed Web of Science ®Google Scholar
• Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388(10055):2015–2022.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747–1757.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Gross L, Trenk D, et al. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. Eur Heart J. 2018;39(29):2749–2758.
   PubMed Web of Science ®Google Scholar
• Gross L, Kupka D, Trenk D, et al. Gender and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: the TROPCAL-ACS gender substudy. Thromb Haemost. 2019;119(9):1527–1538.
   PubMed Web of Science ®Google Scholar
• Orban M, Trenk D, Geisler T, et al. Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: a substudy from the randomized TROPICAL-ACS trial. Eur European Heart J Journal - Cardiovascular Pharmacotherapy. 2020;6(6):372–381.
   PubMed Web of Science ®Google Scholar
• Hein R, Gross L, Aradi D, et al. Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised tropical-acs trial. EuroIntervention. 2019;15(6):513–521.
   Web of Science ®Google Scholar
• Claassens DMF, Vos GJA, Bergmeijer TO, et al. A Genotype-Guided strategy for Oral P2Y 12 Inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–1631.
   PubMed Web of Science ®Google Scholar
• Claassens DMF, Gimbel ME, Bergmeijer TO, et al. Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: a pre-specified sub analysis from the POPular genetics and POPular age trials CYP2C19 alleles in elderly patients. Int J Cardiol. 2021;334:10–17.
   PubMed Web of Science ®Google Scholar
• Claassens DMF, Bergmeijer TO, Vos GJA, et al. Clopidogrel versus ticagrelor or prasugrel after primary percutaneous coronary intervention according to CYP2C19 Genotype: a POPular genetics subanalysis. Circ Cardiovasc Interv. 2021;14(4):402–411.
   Web of Science ®Google Scholar
• Tavenier AH, Claassens DMF, Hermanides RS, et al. Efficacy and safety of glycoprotein IIb/IIIa IIb / IIIa inhibitors in addition to P2Y12 P2Y 12 inhibitors in ST-segment ST -segment elevation myocardial infarction: a subanalysis of the POPular genetics trial. Catheter Cardiovasc Interv. 2021;99(3):676–685.
   PubMed Web of Science ®Google Scholar
• Claassens DMF, van Dorst PWM, Vos GJA, et al. Cost Effectiveness of a CYP2C19 genotype-guided strategy in patients with acute myocardial infarction: results from the pOPular genetics trial. Am J Cardiovasc Drugs. 2022;22(2):195–206.
   PubMed Web of Science ®Google Scholar
• Galli M, Benenati S, Franchi F, et al. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Eur Heart J. 2022;43(10):959–967.
   PubMed Web of Science ®Google Scholar
• Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 2021;397(10283):1470–1483.
   PubMed Web of Science ®Google Scholar
• Laudani C, Greco A, Occhipinti G, et al. Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv. 2022;15(3):268–277.
   PubMed Web of Science ®Google Scholar
• Kuno T, Fujisaki T, Shoji S, et al. Comparison of unguided de-escalation versus guided selection of dual antiplatelet therapy after acute coronary syndrome: a systematic review and network meta-analysis. Circ Cardiovasc Interv. 2022;15(8). DOI:10.1161/CIRCINTERVENTIONS.122.011990.
   PubMed Web of Science ®Google Scholar
• Tavenier AH, Mehran R, Chiarito M, et al. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022;8(5):492–502.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies. Circulation. 2010;121(10):1188–1199.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Rollini F. Switching from prasugrel to clopidogrel: navigating in unknown waters. JACC Cardiovasc Interv. 2013;6(2):166–168.
   PubMed Web of Science ®Google Scholar
• Kerneis M, Silvain J, Abtan J, et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc Interv. 2013;6(2):158–165.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Rios JR, et al. Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease results of the SWAP-4 study. Circulation. 2018;137(23):2450–2462.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Baber U, Bhatt DL, et al. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nat Rev Cardiol. 2022. Available from https://www.nature.com/articles/s41569-022-00725-6
   Web of Science ®Google Scholar